EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Long‐term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large‐cohort retrospective study

Yuan Xu iD, Ying Wang, Ningling Wang, Liya He iD, Jing Ling, Mingwei Jin, Bingshou Xie, Shaohua Le, Meijuan Huang, Jie Peng, Hongbo Cheng, Jiao Jin und 18 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70623 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Yuan Xu und 29 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Ke…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emicizumab is an established prophylactic therapy for haemophilia A (HA). However, real‐world multicentre evidence on long‐term outcomes, particularly in a resource‐constrained setting, remains limited. We aimed to evaluate real‐world outcomes in patients with HA receiving emicizumab prophylaxis across multiple centres with extended follow‐up. We conducted a multicentre retrospective study of patients with HA who received emicizumab prophylaxis for ≥1 year across 25 centres. Outcomes included annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), bleeding events, target joint status and adverse events. A total of 132 patients (131 males and 1 female) were included, with a median age at switch of 2.0 years (interquartile range [IQR], 1.0–4.8). Over a median follow‐up of 26 months (IQR: 16.0–40.0), the negative binomial regression model‐based ABR for all bleeds was 0.81 (95% confidence interval [CI], 0.62–1.07). Across 12‐month intervals, both calculated mean and negative binomial regression model‐based AJBR remained between 0.1 and 0.3. Of the 74 baseline target joints, 95.9% ( n = 71) resolved and no new target joints developed. Forty‐two patients (31.8%) received factor concentrates during emicizumab treatment. Injection‐site reactions occurred in 7.6% of patients, with no thromboembolic or fatal events observed. Long‐term emicizumab prophylaxis provides sustained bleeding control, joint protection and a favourable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedHemophilia AAdultChildChild, PreschoolFemaleHumansInfantMaleChinaFollow-Up StudiesHemorrhageRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

bleedingemicizumabhaemophilia Amachine learningprophylaxis

Substanzen

Antibodies, BispecificAntibodies, Monoclonal, Humanizedemicizumab

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory o…
  • Tianjin Institutes of Health Science, Tianjin, China.
  • Shenzhen Children's Hospital, Shenzhen, China.
  • Department of Pediatrics, The Second Hospital of Anhui Medical University, Hefei, China.
  • Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
  • Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Yuan Xu, Liya He, Li Zhou, Zeping Zhou, Hong Han, Feng Xue, Renchi Yang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
  • Tianjin Municipal Science and Technology Commission
  • Tianjin Municipal Science and Technology Committee

Zitieren

APA

Xu, Y., Wang, Y., Wang, N., He, L., Ling, J., Jin, M., Xie, B., Le, S., Huang, M., Peng, J., Cheng, H., Jin, J., Zhou, L., Zhou, Z., Gai, C., Zhang, Y., Sun, M., Li, X., Yin, J., …, & Yang, R. (2026). Long‐term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large‐cohort retrospective study. British Journal of Haematology. https://doi.org/10.1111/bjh.70623

Vancouver

Xu Y, Wang Y, Wang N, He L, Ling J, Jin M, et al. Long‐term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large‐cohort retrospective study. British Journal of Haematology. 2026. doi:10.1111/bjh.70623

BibTeX
@article{Xu2026,
  author = {Xu, Yuan and Wang, Ying and Wang, Ningling and He, Liya and Ling, Jing and Jin, Mingwei and Xie, Bingshou and Le, Shaohua and Huang, Meijuan and Peng, Jie and Cheng, Hongbo and Jin, Jiao and Zhou, Li and Zhou, Zeping and Gai, Can and Zhang, Yujing and Sun, Mei and Li, Xiaojing and Yin, Jie and Cheng, Yanli and Xue, Ailing and Xu, Weiqun and Han, Hong and Zhang, Fuhua and Zhu, Weiguo and He, Shen and Zhou, Hua and Zhang, Lei and Xue, Feng and Yang, Renchi},
  title = {Long‐term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large‐cohort retrospective study},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70623}
}
Kostenlos starten →